Trial · NCT07483554
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) evaluated according to RECIST v1.1 | Up to 24 months | |
| Primary | Incidence of Adverse Events (AE) | Up to 24 months | |
| Primary | Incidence of treatment-emergent adverse Events (TEAE) | Up to 24 months | |
| Primary | Incidence of adverse events of Special Interest (AESI) | Up to 24 months | |
| Primary | Incidence of serious adverse events (SAE) | Up to 24 months | |
| Primary | Number of participants with abnormal laboratory tests results | Up to 24 months | |
| Primary | Number of subjects with clinically significant changes in physical examination results | Up to 24 months | Clinically significant abnormal physical examination findings reported by the investigator. |
| Primary | Number of subjects with clinically significant changes in vital signs | Up to 24 months | Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure |
| Secondary | Duration of Response (DoR) evaluated according to RECIST v1.1 | Up to 24 months | |
| Secondary | Disease Control Rate (DCR) evaluated according to RECIST v1.1 | Up to 24 months | |
| Secondary | Time to Response (TTR) evaluated according to RECIST v1.1 | Up to 24 months | |
| Secondary | Progression-Free Survival (PFS) evaluated according to RECIST v1.1 | Up to 24 months | |
| Secondary | Overall Survival (OS) | Time to death | |
| Secondary | Area under the concentration-time curve for subjects receiving IBI343 treatment | Up to 24 months | |
| Secondary | Peak concentration for subjects receiving IBI343 treatment | Up to 24 months | |
| Secondary | Time to peak concentration for subjects receiving IBI343 treatment | Up to 24 months | |
| Secondary | Trough concentration for subjects receiving IBI343 treatment | Up to 24 months | |
| Secondary | Clearance for subjects receiving IBI343 treatment. | Up to 24 months | |
| Secondary | Apparent volume of distribution for subjects receiving IBI343 treatment. | Up to 24 months | |
| Secondary | Half-life for subjects receiving IBI343 treatment. | Up to 24 months |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07483554/registered